blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1423406

EP1423406 - RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA) [Right-click to bookmark this link]
StatusPatent maintained as amended
Status updated on  23.10.2015
Database last updated on 21.05.2024
Most recent event   Tooltip17.06.2016Lapse of the patent in a contracting state
New state(s): IT		published on 20.07.2016  [2016/29]
Applicant(s)For all designated states
Sirna Therapeutics, Inc.
300 Third Street
Cambridge MA 02142 / US
[2014/17]
Former [2004/23]For all designated states
Sirna Therapeutics, Inc.
2950 Wilderness Place
Boulder, CO 80301 / US
Inventor(s)01 / MCSWIGGEN, James
4866 Franklin Drive
Boulder, CO 80301 / US
02 / BEIGELMAN, Leonid
5530 Colt Drive
Longmont, CO 80503 / US
03 / CHOWRIRA, Bharat
576 Manorwood Lane
Louisville, CO 80027 / US
04 / PAVCO, Pamela
705 Barberry Circle
Lafayette, CO 80026 / US
05 / FOSNAUGH, Kathy
1030 Edinboro Drive
Boulder, Colorado 80305 / US
06 / JAMISON, Sharon
4985 Twin Lakes Rd 89
Boulder, CO 80301 / US
07 / USMAN, Nassim
2129 Night Sky Lane
Lafayette, CO 80026 / US
08 / THOMPSON, James
705 Barberry Circle
Lafayette, CO 80026 / US
 [2004/23]
Representative(s)Potter Clarkson
Chapel Quarter
Mount Street
Nottingham NG1 6HQ / GB
[N/P]
Former [2015/48]Potter Clarkson LLP
The Belgrave Centre
Talbot Street
Nottingham, NG1 5GG / GB
Former [2013/37]Potter Clarkson LLP
The Belgrave Centre
Talbot Street
Nottingham
NG1 5GG / GB
Former [2011/51]Pilkington, Stephanie Joan, et al
Potter Clarkson LLP Park View House 58 The Ropewalk Nottingham
NG1 5DD / GB
Former [2008/32]Rollins, Anthony John, et al
Merck Sharp & Dohme Limited European Patent Department Hertford Road Hoddesdon
Hertfordshire EN11 9BU / GB
Former [2008/22]Rollins, Anthony John, et al
Merck Sharp & Dohme Limited Hertford Road Hoddesdon Herts
EN11 9BU / GB
Former [2004/23]Maschio, Antonio, Dr.
D Young & Co, 21 New Fetter Lane
London EC4A 1DA / GB
Application number, filing date03743684.720.02.2003
[2004/23]
WO2003US05028
Priority number, dateUS20020358580P20.02.2002         Original published format: US 358580 P
US20020363124P11.03.2002         Original published format: US 363124 P
US20020386782P06.06.2002         Original published format: US 386782 P
US20020406784P29.08.2002         Original published format: US 406784 P
US20020408378P05.09.2002         Original published format: US 408378 P
US20020409293P09.09.2002         Original published format: US 409293 P
US20030440129P15.01.2003         Original published format: US 440129 P
[2004/23]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO03074654
Date:12.09.2003
Language:EN
[2003/37]
Type: A2 Application without search report 
No.:EP1423406
Date:02.06.2004
Language:EN
The application published by WIPO in one of the EPO official languages on 12.09.2003 takes the place of the publication of the European patent application.
[2004/23]
Type: B1 Patent specification 
No.:EP1423406
Date:01.09.2010
Language:EN
[2010/35]
Type: B2 New European patent specification 
No.:EP1423406
Date:25.11.2015
Language:EN
[2015/48]
Search report(s)International search report - published on:US05.02.2004
(Supplementary) European search report - dispatched on:EP23.03.2005
ClassificationIPC:C12Q1/68, C12P19/34, C12N15/85, C12N15/86, C07H21/02, C07H21/04, A61K48/00
[2005/18]
CPC:
C12N15/8218 (EP,US); A61K47/54 (EP,US); A61P1/00 (EP);
A61P1/04 (EP); A61P1/16 (EP); A61P11/00 (EP);
A61P11/06 (EP); A61P13/08 (EP); A61P13/10 (EP);
A61P13/12 (EP); A61P15/00 (EP); A61P17/00 (EP);
A61P17/02 (EP); A61P19/00 (EP); A61P19/02 (EP);
A61P21/00 (EP); A61P25/00 (EP); A61P25/02 (EP);
A61P25/08 (EP); A61P25/14 (EP); A61P25/16 (EP);
A61P25/28 (EP); A61P27/02 (EP); A61P27/16 (EP);
A61P29/00 (EP); A61P3/00 (EP); A61P3/10 (EP);
A61P31/00 (EP); A61P31/04 (EP); A61P31/10 (EP);
A61P31/12 (EP); A61P31/14 (EP); A61P31/16 (EP);
A61P31/18 (EP); A61P31/20 (EP); A61P31/22 (EP);
A61P35/00 (EP); A61P35/02 (EP); A61P37/00 (EP);
A61P37/04 (EP); A61P37/06 (EP); A61P37/08 (EP);
A61P41/00 (EP); A61P43/00 (EP); A61P5/00 (EP);
A61P9/00 (EP); A61P9/10 (EP); C07H21/02 (EP,US);
C12N15/111 (EP,US); C12N15/1131 (EP,US); C12N15/1138 (EP,US);
A61K38/00 (EP,US); C12N2310/111 (EP,US); C12N2310/14 (EP,US);
C12N2310/315 (EP,US); C12N2310/317 (EP,US); C12N2310/318 (EP,US);
C12N2310/321 (EP,US); C12N2310/322 (EP,US); C12N2310/332 (EP,US);
C12N2310/344 (EP,US); C12N2310/346 (EP,US); C12N2310/53 (EP,US);
C12N2320/51 (EP,US); C12N2330/30 (EP,US); Y02A50/30 (EP,US) (-)
C-Set:
C12N2310/321, C12N2310/3521 (EP,US)
Former IPC [2004/23]C07H21/04, A61K48/00, C12N15/85, C12N15/86, C12P19/34, C12Q1/68
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IT,   LI,   LU,   MC,   NL,   PT,   SE,   SI,   SK,   TR [2015/48]
Former [2004/23]AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HU,  IE,  IT,  LI,  LU,  MC,  NL,  PT,  SE,  SI,  SK,  TR 
TitleGerman:DURCH RNA-INTERFERENZ VERMITTELTE HEMMUNG DER GENEXPRESSION UNTER VERWENDUNG VON SINA (SHORT INTERFERING NUCLEIC ACID)[2004/23]
English:RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA)[2004/23]
French:INTERFERENCE ARN PERMETTANT D'INHIBER L'EXPRESSION D'UN GENE A L'AIDE D'UN ACIDE NUCLEIQUE INTERFERANT COURT (SINA)[2004/23]
Entry into regional phase17.02.2004National basic fee paid 
17.02.2004Search fee paid 
17.02.2004Designation fee(s) paid 
17.02.2004Examination fee paid 
Examination procedure17.02.2004Examination requested  [2004/23]
24.03.2004Amendment by applicant (claims and/or description)
25.07.2005Despatch of a communication from the examining division (Time limit: M04)
02.11.2005Reply to a communication from the examining division
12.12.2005Despatch of a communication from the examining division (Time limit: M04)
11.01.2006Reply to a communication from the examining division
12.10.2007Despatch of a communication from the examining division (Time limit: M08)
23.06.2008Reply to a communication from the examining division
13.11.2009Date of oral proceedings
15.02.2010Minutes of oral proceedings despatched
03.03.2010Communication of intention to grant the patent
19.03.2010Fee for grant paid
19.03.2010Fee for publishing/printing paid
Divisional application(s)EP06075987.5  / EP1710307
EP10008929.1  / EP2287305
EP10008930.9  / EP2287306
EP10008931.7  / EP2278004
EP14195627.6  / EP2902406
EP17209752.9  / EP3354656
EP18203871.1  / EP3459963
EP21166750.6  / EP3926046
Opposition(s)Opponent(s)01  18.05.2011  24.09.2014  WITHDRAWN
Sanofi-Aventis Deutschland GmbH
Industriepark Höchst Bldg. K801
65926 Frankfurt am Main / DE
Opponent's representative
Bösl, Raphael Konrad, et al, et al
Patentanwälte Isenbruck Bösl Hörschler PartG mbB
Eastsite One
Seckenheimer Landstraße 4
68163 Mannheim / DE
 02  26.05.2011  01.06.2011  ADMISSIBLE
Novartis AG
Lichtstrasse 35
4056 Basel / CH
Opponent's representative
Bullett, Rachel Margaret, et al, et al
Carpmaels & Ransford LLP
One Southampton Row
London WC1B 5HA / GB
 03  31.05.2011  04.03.2014  WITHDRAWN
Alnylam Pharmaceuticals Inc.
300 Third street, Third Floor
Cambridge MA 02142 / US
Opponent's representative
Vossius & Partner Patentanwälte Rechtsanwälte mbB, et al, et al
Siebertstrasse 3
81675 München / DE
 04  31.05.2011  09.06.2011  ADMISSIBLE
Thermo Fisher Scientific Biosciences Inc.
2650 Crescent Drive, Suite 100
Lafayette, CO 80026 / US
Opponent's representative
Vossius & Partner Patentanwälte Rechtsanwälte mbB, et al, et al
Siebertstrasse 3
81675 München / DE
 05  01.06.2011  10.06.2011  ADMISSIBLE
Alcon Research, Ltd.
6201 South Freeway, Mail Code TB4-8
Fort Worth, TX 76134-2099 / US
Opponent's representative
Kalhammer, Georg, et al, et al
Lederer & Keller
Patentanwälte Partnerschaft mbB
Unsöldstrasse 2
80538 München / DE
 [N/P]
Former [2015/19]
Opponent(s)01  18.05.2011  24.09.2014  WITHDRAWN
Sanofi-Aventis Deutschland GmbH
Industriepark Höchst Bldg. K801
65926 Frankfurt am Main / DE
Opponent's representative
Bösl, Raphael Konrad, et al, et al
Isenbruck Bösl Hörschler LLP
Patentanwälte
Prinzregentenstraße 68
81675 München / DE
 02  26.05.2011  01.06.2011  ADMISSIBLE
Novartis AG
Lichtstrasse 35
4056 Basel / CH
Opponent's representative
Bullett, Rachel Margaret, et al, et al
Carpmaels & Ransford LLP
One Southampton Row
London WC1B 5HA / GB
 03  31.05.2011  04.03.2014  WITHDRAWN
Alnylam Pharmaceuticals Inc.
300 Third street, Third Floor
Cambridge MA 02142 / US
Opponent's representative
Vossius & Partner Patentanwälte Rechtsanwälte mbB, et al, et al
Siebertstrasse 3
81675 München / DE
 04  31.05.2011  09.06.2011  ADMISSIBLE
Thermo Fisher Scientific Biosciences Inc.
2650 Crescent Drive, Suite 100
Lafayette, CO 80026 / US
Opponent's representative
Vossius & Partner Patentanwälte Rechtsanwälte mbB, et al, et al
Siebertstrasse 3
81675 München / DE
 05  01.06.2011  10.06.2011  ADMISSIBLE
Alcon Research, Ltd.
6201 South Freeway, Mail Code TB4-8
Fort Worth, TX 76134-2099 / US
Opponent's representative
Kalhammer, Georg, et al, et al
Lederer & Keller
Patentanwälte Partnerschaft mbB
Unsöldstrasse 2
80538 München / DE
Former [2014/45]
Opponent(s)01  18.05.2011  24.09.2014  WITHDRAWN
Sanofi-Aventis Deutschland GmbH
Industriepark Höchst Bldg. K801
65926 Frankfurt am Main / DE
Opponent's representative
Bösl, Raphael Konrad, et al, et al
Isenbruck Bösl Hörschler LLP Patentanwälte Prinzregentenstrasse 68
81675 München / DE
 02  26.05.2011  01.06.2011  ADMISSIBLE
Novartis AG
Lichtstrasse 35
4056 Basel / CH
Opponent's representative
Bullett, Rachel Margaret, et al, et al
Carpmaels & Ransford LLP
One Southampton Row
London WC1B 5HA / GB
 03  31.05.2011  04.03.2014  WITHDRAWN
Alnylam Pharmaceuticals Inc.
300 Third street, Third Floor
Cambridge MA 02142 / US
Opponent's representative
Wachenfeld, Joachim, et al, et al
Vossius & Partner Siebertstrasse 4
81675 München / DE
 04  31.05.2011  09.06.2011  ADMISSIBLE
Thermo Fisher Scientific Biosciences Inc.
2650 Crescent Drive, Suite 100
Lafayette, CO 80026 / US
Opponent's representative
Wachenfeld, Joachim, et al, et al
Vossius & Partner Siebertstrasse 4
81675 München / DE
 05  01.06.2011  10.06.2011  ADMISSIBLE
Alcon Research, Ltd.
6201 South Freeway, Mail Code TB4-8
Fort Worth, TX 76134-2099 / US
Opponent's representative
Kalhammer, Georg, et al, et al
Lederer & Keller
Patentanwälte Partnerschaft mbB
Unsöldstrasse 2
80538 München / DE
Former [2014/15]
Opponent(s)01  18.05.2011  25.05.2011  ADMISSIBLE
Sanofi-Aventis Deutschland GmbH
Industriepark Höchst Bldg. K801
65926 Frankfurt am Main / DE
Opponent's representative
Bösl, Raphael Konrad, et al, et al
Isenbruck Bösl Hörschler LLP Patentanwälte Prinzregentenstrasse 68
81675 München / DE
 02  26.05.2011  01.06.2011  ADMISSIBLE
Novartis AG
Lichtstrasse 35
4056 Basel / CH
Opponent's representative
Bullett, Rachel Margaret, et al, et al
Carpmaels & Ransford LLP
One Southampton Row
London WC1B 5HA / GB
 03  31.05.2011  04.03.2014  WITHDRAWN
Alnylam Pharmaceuticals Inc.
300 Third street, Third Floor
Cambridge MA 02142 / US
Opponent's representative
Wachenfeld, Joachim, et al, et al
Vossius & Partner Siebertstrasse 4
81675 München / DE
 04  31.05.2011  09.06.2011  ADMISSIBLE
Thermo Fisher Scientific Biosciences Inc.
2650 Crescent Drive, Suite 100
Lafayette, CO 80026 / US
Opponent's representative
Wachenfeld, Joachim, et al, et al
Vossius & Partner Siebertstrasse 4
81675 München / DE
 05  01.06.2011  10.06.2011  ADMISSIBLE
Alcon Research, Ltd.
6201 South Freeway, Mail Code TB4-8
Fort Worth, TX 76134-2099 / US
Opponent's representative
Kalhammer, Georg, et al, et al
Lederer & Keller Patentanwälte Unsöldstrasse 2
80538 München / DE
Former [2013/39]
Opponent(s)01  18.05.2011  25.05.2011  ADMISSIBLE
Sanofi-Aventis Deutschland GmbH
Industriepark Höchst Bldg. K801
65926 Frankfurt am Main / DE
Opponent's representative
Bösl, Raphael Konrad, et al, et al
Isenbruck Bösl Hörschler LLP Patentanwälte Prinzregentenstrasse 68
81675 München / DE
 02  26.05.2011  01.06.2011  ADMISSIBLE
Novartis AG
Lichtstrasse 35
4056 Basel / CH
Opponent's representative
Bullett, Rachel Margaret, et al, et al
Carpmaels & Ransford LLP
One Southampton Row
London
WC1B 5HA / GB
 03  31.05.2011  09.06.2011  ADMISSIBLE
Alnylam Pharmaceuticals Inc.
300 Third street, Third Floor
Cambridge MA 02142 / US
Opponent's representative
Wachenfeld, Joachim, et al, et al
Vossius & Partner Siebertstrasse 4
81675 München / DE
 04  31.05.2011  09.06.2011  ADMISSIBLE
Thermo Fisher Scientific Biosciences Inc.
2650 Crescent Drive, Suite 100
Lafayette, CO 80026 / US
Opponent's representative
Wachenfeld, Joachim, et al, et al
Vossius & Partner Siebertstrasse 4
81675 München / DE
 05  01.06.2011  10.06.2011  ADMISSIBLE
Alcon Research, Ltd.
6201 South Freeway, Mail Code TB4-8
Fort Worth, TX 76134-2099 / US
Opponent's representative
Kalhammer, Georg, et al, et al
Lederer & Keller Patentanwälte Unsöldstrasse 2
80538 München / DE
Former [2011/28]
Opponent(s)01  18.05.2011  25.05.2011  ADMISSIBLE
Sanofi-Aventis Deutschland GmbH
Industriepark Höchst Bldg. K801
65926 Frankfurt am Main / DE
Opponent's representative
Bösl, Raphael Konrad, et al, et al
Isenbruck Bösl Hörschler LLP Patentanwälte Prinzregentenstrasse 68
81675 München / DE
 02  26.05.2011  01.06.2011  ADMISSIBLE
Novartis AG
Lichtstrasse 35
4056 Basel / CH
Opponent's representative
Bullett, Rachel Margaret, et al, et al
Carpmaels & Ransford One Southampton Row London
WC1B 5HA / GB
 03  31.05.2011  09.06.2011  ADMISSIBLE
Alnylam Pharmaceuticals Inc.
300 Third street, Third Floor
Cambridge MA 02142 / US
Opponent's representative
Wachenfeld, Joachim, et al, et al
Vossius & Partner Siebertstrasse 4
81675 München / DE
 04  31.05.2011  09.06.2011  ADMISSIBLE
Dharmacon, Inc.
2650 Crescent Drive, Suite 100
Lafayette, CO 80026 / US
Opponent's representative
Wachenfeld, Joachim, et al, et al
Vossius & Partner Siebertstrasse 4
81675 München / DE
 05  01.06.2011    ADMISSIBLE
Alcon Research, Ltd.
6201 South Freeway, Mail Code TB4-8
Fort Worth, TX 76134-2099 / US
Opponent's representative
Kalhammer, Georg, et al, et al
Lederer & Keller Patentanwälte Unsöldstrasse 2
80538 München / DE
Former [2011/26]
Opponent(s)01  18.05.2011  25.05.2011  ADMISSIBLE
Sanofi-Aventis Deutschland GmbH
Industriepark Höchst Bldg. K801
65926 Frankfurt am Main / DE
Opponent's representative
Bösl, Raphael Konrad, et al, et al
Isenbruck Bösl Hörschler LLP Patentanwälte Prinzregentenstrasse 68
81675 München / DE
 02  26.05.2011    ADMISSIBLE
Novartis AG
Lichtstrasse 35
4056 Basel / CH
Opponent's representative
Bullett, Rachel Margaret, et al, et al
Carpmaels & Ransford One Southampton Row London
WC1B 5HA / GB
Former [2011/25]
Opponent(s)01  18.05.2011    WITHDRAWN
Sanofi-Aventis Deutschland GmbH
Industriepark Höchst Bldg. K801
65926 Frankfurt am Main / DE
Opponent's representative
Bösl, Raphael Konrad, et al, et al
Isenbruck Bösl Hörschler LLP Patentanwälte Prinzregentenstrasse 68
81675 München / DE
06.07.2011Invitation to proprietor to file observations on the notice of opposition
09.11.2011Reply of patent proprietor to notice(s) of opposition
01.04.2014Legal effect of interlocutory decision in opposition
01.04.2014Date of oral proceedings
25.04.2014Despatch of minutes of oral proceedings
16.04.2015Despatch of interlocutory decision in opposition
07.08.2015Despatch of communication that the patent will be maintained as amended
19.10.2015Fee for printing new specification paid
Fees paidRenewal fee
22.02.2005Renewal fee patent year 03
27.02.2006Renewal fee patent year 04
27.02.2007Renewal fee patent year 05
25.02.2008Renewal fee patent year 06
26.02.2009Renewal fee patent year 07
08.02.2010Renewal fee patent year 08
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipCY01.09.2010
CZ01.09.2010
EE01.09.2010
HU01.09.2010
SI01.09.2010
SK01.09.2010
TR01.09.2010
BG01.12.2010
GR02.12.2010
PT03.01.2011
LU20.02.2011
MC28.02.2011
AT20.02.2014
FI20.02.2014
IE20.02.2014
IT20.02.2014
ES21.02.2014
SE21.02.2014
BE28.02.2014
DK28.02.2014
[2016/29]
Former [2015/33]CY01.09.2010
CZ01.09.2010
EE01.09.2010
HU01.09.2010
SI01.09.2010
SK01.09.2010
TR01.09.2010
BG01.12.2010
GR02.12.2010
PT03.01.2011
LU20.02.2011
MC28.02.2011
AT20.02.2014
FI20.02.2014
IE20.02.2014
ES21.02.2014
SE21.02.2014
BE28.02.2014
DK28.02.2014
Former [2015/08]CY01.09.2010
CZ01.09.2010
EE01.09.2010
HU01.09.2010
SI01.09.2010
SK01.09.2010
TR01.09.2010
BG01.12.2010
GR02.12.2010
PT03.01.2011
LU20.02.2011
MC28.02.2011
AT20.02.2014
FI20.02.2014
IE20.02.2014
SE21.02.2014
BE28.02.2014
DK28.02.2014
Former [2015/07]CY01.09.2010
CZ01.09.2010
EE01.09.2010
HU01.09.2010
SI01.09.2010
SK01.09.2010
TR01.09.2010
BG01.12.2010
GR02.12.2010
PT03.01.2011
LU20.02.2011
MC28.02.2011
AT20.02.2014
FI20.02.2014
IE20.02.2014
SE21.02.2014
Former [2014/51]CY01.09.2010
CZ01.09.2010
EE01.09.2010
HU01.09.2010
SI01.09.2010
SK01.09.2010
TR01.09.2010
BG01.12.2010
GR02.12.2010
PT03.01.2011
LU20.02.2011
MC28.02.2011
AT20.02.2014
FI20.02.2014
SE21.02.2014
Former [2014/50]CY01.09.2010
CZ01.09.2010
EE01.09.2010
HU01.09.2010
SI01.09.2010
SK01.09.2010
TR01.09.2010
BG01.12.2010
GR02.12.2010
PT03.01.2011
LU20.02.2011
MC28.02.2011
FI20.02.2014
SE21.02.2014
Former [2014/49]CY01.09.2010
CZ01.09.2010
EE01.09.2010
HU01.09.2010
SI01.09.2010
SK01.09.2010
TR01.09.2010
BG01.12.2010
GR02.12.2010
PT03.01.2011
LU20.02.2011
MC28.02.2011
FI20.02.2014
Former [2013/45]CY01.09.2010
CZ01.09.2010
EE01.09.2010
HU01.09.2010
SI01.09.2010
SK01.09.2010
TR01.09.2010
BG01.12.2010
GR02.12.2010
PT03.01.2011
LU20.02.2011
MC28.02.2011
Former [2013/44]CY01.09.2010
CZ01.09.2010
EE01.09.2010
SI01.09.2010
SK01.09.2010
TR01.09.2010
BG01.12.2010
GR02.12.2010
PT03.01.2011
LU20.02.2011
MC28.02.2011
Former [2013/42]CY01.09.2010
CZ01.09.2010
EE01.09.2010
SI01.09.2010
SK01.09.2010
BG01.12.2010
GR02.12.2010
PT03.01.2011
LU20.02.2011
MC28.02.2011
Former [2011/24]CY01.09.2010
CZ01.09.2010
EE01.09.2010
SI01.09.2010
SK01.09.2010
GR02.12.2010
PT03.01.2011
Former [2011/23]CY01.09.2010
CZ01.09.2010
EE01.09.2010
SI01.09.2010
SK01.09.2010
GR02.12.2010
Former [2011/15]CY01.09.2010
SI01.09.2010
GR02.12.2010
Former [2011/13]CY01.09.2010
SI01.09.2010
Former [2011/10]SI01.09.2010
Documents cited:Search[Y]WO9904819  (INEX PHARMACEUTICALS CORP [CA], et al) [Y] 1-24 * page 29; example VI * * page 34; example 6; claim 5 *;
 [A]WO0021560  (LUDWIG INST CANCER RES [US], et al) [A] 1-24* abstract *;
 [XY]  - ELBASHIR SAYDA M ET AL, "RNA interference is mediated by 21- and 22-nucleotide RNAs", GENES AND DEVELOPMENT, COLD SPRING HARBOR LABORATORY PRESS, NEW YORK, US, (20010115), vol. 15, no. 2, ISSN 0890-9369, pages 188 - 200, XP002204651 [X] 1,2 * page 193, column L, paragraph 3 * [Y] 1-24

DOI:   http://dx.doi.org/10.1101/gad.862301
 [XY]  - BASS B L, "RNA interference: the short answer", NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, (20010524), vol. 411, ISSN 0028-0836, pages 428 - 429, XP002239989 [X] 1,2 * page 428, column R, paragraph 3 - page 429, column L, paragraph 1 * [Y] 1-24

DOI:   http://dx.doi.org/10.1038/35078175
 [Y]  - HASAN J ET AL, "VEGF ANTAGONISTS", EXPERT OPINION ON BIOLOGICAL THERAPY, ASHLEY, LONDON, GB, (200107), vol. 1, no. 4, ISSN 1471-2598, pages 703 - 718, XP009032174 [Y] 1-24 * page 706, column L, line 12 - column R, paragraph 4 *

DOI:   http://dx.doi.org/10.1517/14712598.1.4.703
International search[X]WO9401550  (HYBRIDON INC [US], et al);
 [Y]US5814620  (ROBINSON GREGORY S [US], et al);
 [X]WO9932619  (CARNEGIE INST OF WASHINGTON [US], et al);
 [Y]WO9949029  (GENE AUSTRALIA LIMITED AG [AU], et al);
 [X]WO0044914  (MED COLLEGE GEORGIA RES INST [US], et al);
 [X]CA2359180  (LIMMER STEPHAN [DE], et al);
 [YP]WO0136646  (CANCER RES CAMPAIGN TECH [GB], et al);
 [YP]WO0222636  (ISIS PHARMACEUTICALS INC [US], et al);
 [AP]US6506559  (FIRE ANDREW [US], et al);
 [YP]  - FUTAMI ET AL, "Induction of apoptosis in HeLa cells with siRNA expression vector targeted against bcl-2", NUCLEIC ACIDS RESEARCH SUPPLEMENT, (200201), no. 2, pages 251 - 252, XP002968175
 [XP]  - TUSCHL ET AL, "Small interfering RNAs: a revolutionary tool for the analysis of gene function and gene therapy", MOLECULAR INTERVENTIONS, (200206), vol. 295, no. 3, pages 158 - 167, XP002294002
 [XP]  - LEIRDAL ET AL, "Gene silencing in mammalian cells by preformed small RNA duplexes", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, (200206), vol. 295, pages 744 - 748, XP002953281

DOI:   http://dx.doi.org/10.1016/S0006-291X(02)00736-2
 [X]  - LIN ET AL, "A novel mRNA-cDNA interference phenomenon for silencing bcl-2 expression in human LNCaP cells", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, (200101), vol. 281, pages 639 - 644, XP002230694

DOI:   http://dx.doi.org/10.1006/bbrc.2001.4412
 [X]  - FIRE ET AL, "Potent and specific genetic interference by double-stranded RNA in caenorhabditis elegans", NATURE, (19980219), vol. 391, pages 806 - 811, XP002095876

DOI:   http://dx.doi.org/10.1038/35888
 [X]  - ELBASHIR ET AL, "Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells", NATURE, (20010524), vol. 411, pages 494 - 498, XP002206451

DOI:   http://dx.doi.org/10.1038/35078107
 [X]  - TUSCHL ET AL, "Targeted mRNA degradation by double-stranded RNA in vitro", GENES AND DEVELOPMENT, (19991215), vol. 13, no. 24, pages 3191 - 3197, XP002183118

DOI:   http://dx.doi.org/10.1101/gad.13.24.3191
 [YP]  - ELBASHIR ET AL, "Functional anatomy of siRNAs for mediating efficient RNAi in drosophila melanogaster embryo lysate", THE EMBO JOURNAL, (200110), vol. 20, no. 23, pages 6877 - 6888, XP002225998

DOI:   http://dx.doi.org/10.1093/emboj/20.23.6877
ExaminationWO9929350
 US5998203
 WO0044895
 WO0153528
 WO0168836
 WO0175164
 WO0244321
 WO03070881
 WO03070918
 WO03099227
 EP1389637
 WO2005003350
    - PARRISH S. ET AL, "Functional anatomy of a dsRNA trigger: Differential requirement for the two trigger strands in RNA interference", MOLECULAR CELL, (20001101), vol. 6, no. 5, pages 1077 - 1087, XP002226298

DOI:   http://dx.doi.org/10.1016/S1097-2765(00)00106-4
    - KENNERDELL JASON R.; CARTHEW RICHARD W., "Heritable gene silencing in Drosophila using double-stranded RNA", NATURE BIOTECHNOLOGY, (200008), vol. 18, no. 8, pages 896 - 898
    - TAVERNARAKIS N. ET AL, "HERITABLE AND INDUCIBLE GENETIC INTERFERENCE BY DOUBLE-STRANDED RNA ENCODED BY TRANSGENES", NATURE GENETICS, (20000201), vol. 24, pages 180 - 183, XP002938530

DOI:   http://dx.doi.org/10.1038/72850
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.